Posts by: Alice Melão

All three relapsed or refractory multiple myeloma patients in the final group of Cellectar Biosciences‘ Phase 1 trial of CLR 131 benefited from treatment, researchers said. Participants had received more than five ... Read more

October 4, 2017October 4, 2017

Acupuncture Helps to Manage Effects of HSCT and Chemo in Myeloma Patients, Study Says

News

Acupuncture can help ease the nausea and drowsiness that follows an autologous hematopoietic stem cell transplant in multiple myeloma patients, a new study suggests. These symptoms can be common in ... Read more

September 29, 2017September 29, 2017

Japanese Regulator Approves Darzalex Combo for Relapsed or Refractory Multiple Myeloma

News

The Japanese Ministry of Health, Labor, and Welfare has approved Darzalex (daratumumab) in combination with either Revlimid (lenalidomide) and dexamethasone, or Velcade (bortezomib) and dexamethasone, for the treatment of adults with relapsed or refractory ... Read more

September 15, 2017September 15, 2017

Unum’s T-Cell Therapy Enters Phase 1 Trial for Relapsed or Refractory Multiple Myeloma

News

The U.S. Food and Drug Administration (FDA) recently approved an investigational new drug (IND) application filed by Unum Therapeutics for its ACTR087 T-cell therapy to be used in combination ... Read more

September 6, 2017

Long-term Data Confirms Kyprolis Survival Benefit in Relapsed Myeloma Patients

News

New long-term data from the Phase 3 ENDEAVOR trial has shown that relapsed multiple myeloma patients treated with Kyprolis (carfilzomib) plus dexamethasone survive a median of nine months longer than ... Read more

August 4, 2017August 4, 2017

Imbruvica Becomes 1st FDA-Approved Therapy for Graft-Versus-Host-Disease in Adults

News

The U.S. Food and Drug Administration (FDA) has approved Imbruvica (ibrutinib) for the treatment of chronic graft-versus-host-disease (cGVHD), a common complication of stem cell or bone marrow transplant, in adult patients ... Read more

July 31, 2017July 31, 2017

STRO-001 Eliminates or Slows Growth of Myeloma and Lymphoma in Mice, Studies Show

News

Sutro Biopharma‘s STRO-001 eliminates or significantly slows the growth of non-Hodgkin lymphoma and multiple myeloma tumors, studies in mice indicate. Sutro expects the results to support its investigational new drug application for ... Read more

June 2, 2017

Adding Darzalex to Standard Therapies in Multiple Myeloma Patients Continues to Show Improved Results

News

Adding Darzalex (daratumumab) to standard care therapies continues to show improved effectiveness in treating relapsed or refractory multiple myeloma, with no related toxicity, according to updated results from the ongoing Phase 3 ... Read more

May 8, 2017May 8, 2017

One World Cannabis to Test Mice in Pursuit of Therapies Targeting Multiple Myeloma Cancer Cells

News

Israel’s One World Cannabis (OWC) says it’s moving forward to mouse models to test its unique formula of cannabinoid-based therapies targeting cancer cells. This decision followed promising results from preclinical in vitro studies. ... Read more

May 5, 2017May 22, 2017

Darzalex Approved in Europe as Combo Therapy for Advanced Multiple Myeloma

News

Janssen’s Darzalex (daratumumab) received full approval by the European Commission (EC) for use in treating adult patients with multiple myeloma who have received at least one prior therapy. The EC approved ... Read more